The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRTA | -38.09% | -13.58% | -2.88% | +44% |
| S&P | +15.06% | +95.03% | +14.29% | +371% |
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Promising drug candidates could lead to a best-in-class Alzheimer's treatment.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.42M | -96.7% |
| Gross Profit | $3.54M | -97.3% |
| Gross Margin | 80.02% | -19.3% |
| Market Cap | $326.73M | -70.6% |
| Market Cap / Employee | $2.00M | 0.0% |
| Employees | 163 | -5.8% |
| Net Income | -$125.77M | -288.0% |
| EBITDA | -$51.12M | -186.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $371.44M | -34.2% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.93M | -27.4% |
| Short Term Debt | $2.85M | 10.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.00% | -50.5% |
| Return On Invested Capital | -22.33% | 0.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$50.28M | -413.4% |
| Operating Free Cash Flow | -$50.19M | -410.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.68 | 1.39 | 1.37 | 0.75 | -66.18% |
| Price to Sales | 6.75 | 5.51 | 4.83 | 31.60 | 504.18% |
| Price to Tangible Book Value | 1.68 | 1.39 | 1.37 | 0.75 | -66.18% |
| Enterprise Value to EBITDA | -5.98 | -4.45 | -4.00 | 0.68 | -93.07% |
| Return on Equity | -22.9% | -23.3% | -23.5% | -66.9% | 663.79% |
| Total Debt | $11.49M | $10.84M | $10.20M | $9.78M | -19.28% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
